Damian Garde

Biography for Damian Garde

Damian Garde, Editor

Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at dgarde@fiercemarkets.com and follow @DamianFierce on Twitter.

Articles by Damian Garde

CRO Accovion rolls into Italy with eyes on France

German-headquartered CRO Accovion is expanding its reach in Europe, opening a new shop in Italy and planning to launch a French subsidiary in the fall.

Amid global expansion, India's GVK focuses on clinical development

Indian CRO GVK Biosciences has spent the last year transitioning from a discovery-focused contractor to a full-service developer, now launching a dedicated clinical research unit to reach drugmakers around the world.

Theorem eyes an Indian expansion with latest partnership

CRO Theorem Clinical Research has inked a deal with India's Excel Life Sciences to broaden its footprint in the country, expanding its access to clinical trial sites and bolstering its patient-recruitment capabilities.

Post-buyout Harlan inks a CRO partnership with Fluofarma

Months removed from getting bought by Huntingdon Life Sciences, Harlan Laboratories has teamed up with a French CRO to expand its capabilities in drug discovery and translational medicine.

CRO Chiltern snags rival Ockham to bolster its oncology footprint

Chiltern has acquired Ockham, a fellow contract researcher, planning to absorb the company's capabilities and expand its service offerings.

Catalent shoots for $872M in a blockbuster IPO

Pharma contracting giant Catalent has jumbo-sized its Wall Street ambitions, filing to go public in an IPO that would bring in about $872 million at its midpoint.

China's HD Bio teams with Marshall U. for cancer R&D

Chinese clinical research outfit HD Biosciences has struck a deal with Marshall University to collaborate on cancer drug development, sharing costs and risks in hopes of commercializing new therapies.

NCI backs out of a $34M deal with Charles River, putting jobs in jeopardy

The National Cancer Institute is terminating a $34 million mouse-model contract with Charles River Laboratories, possibly imperiling jobs at one of the CRO's Maryland outposts.

CMOs eye Russia for growth

Russia is striving to produce domestically 50% of the drugs sold in the country, and, to do so, it's encouraging global manufacturers to buy, build or rent facilities there.

InVentiv joins a nonprofit effort to make trials more efficient

CRO inVentiv Health has agreed to share its expertise with the nonprofit Alliance for Clinical Research Excellence and Safety (ACRES), working to develop global standards for clinical trials.